Different types of adjuvants in prophylactic and therapeutic human papillomavirus vaccines in laboratory animals: a systematic review.
Arch Virol
; 165(2): 263-284, 2020 Feb.
Article
em En
| MEDLINE
| ID: mdl-31802228
ABSTRACT
Human papillomavirus (HPV) causes cervical carcinoma, which and is the third most common cancer, accounting for 275,000 deaths annually worldwide. Adjuvants have a key role in promotion of vaccine efficacy; therefore, using prophylactic and therapeutic vaccines combined with adjuvant could be of great benefit in prevention and treatment of cervical cancer. There are different types of adjuvants, including MF59TM adjuvants, RNA-based, JY (interleukin2/chitosan), cholera toxin (CT), heat-labile enterotoxin (LT), Freund's adjuvant, alum, SA-4-1BBL, λ-carrageenan (λ-CGN), heat shock proteins (HSPs), juzen-taiho-to (JTT) and hochu-ekki-to (HET), ISCOM and ISCOMATRIX™, very small size proteoliposomes (VSSPs), granulocyte macrophage colony-stimulating factor (GM-CSF), and Toll-like receptors (TLRs). Adjuvants have various functions, especially in therapeutic vaccines, and they lead to an increase in cytotoxic T lymphocytes (CTLs), so they are important in the design of vaccines. Here, we review the currently used adjuvants and their combinations with HPV protein vaccines in order to introduce an appropriate adjuvant for HPV vaccines.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Papillomaviridae
/
Neoplasias do Colo do Útero
/
Adjuvantes Imunológicos
/
Infecções por Papillomavirus
/
Vacinas contra Papillomavirus
Tipo de estudo:
Prognostic_studies
/
Systematic_reviews
Limite:
Animals
Idioma:
En
Revista:
Arch Virol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Irã